EligibleTrials

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Recruiting · NCT05740722 · Interventional (participants receive a specific treatment) · Lead sponsor: Haukeland University Hospital

View the official record on ClinicalTrials.gov →
Multiple Sclerosis

Interventions studied

Nicotinamid ribosidePlacebo

What this trial is about

The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,

Who can take part

Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.